Influence of recombinant human erythropoietin therapy on plasma level of insulin-like growth factor type 1 (IGF-1) in chronic hemodialysis patients. - Egyptian Knowledge Bank - troweb

37445

Influence of recombinant human erythropoietin therapy on plasma level of insulin-like growth factor type 1 (IGF-1) in chronic hemodialysis patients.

Thesis

Last updated: 06 Feb 2023

Overview Similar Items

Thesis

Effect of recombinant human erythropoietin on the parathyroid function and bone density in uremic patients under regular hemodialysis

Thesis

Target haemoglobin in the treatment of anaemia of chronic renal failure by recombinant human erythropoietin

Thesis

Study of the influence of erythropoietin treatment on hemoglobin Alc levels in diabetic patients with chronic renal failure on hemodialysis

Thesis

The resistance to recombinant human erythropoietin (rHuEPO) therapy in patients having chronic renal failure due to inflammation

Thesis

Diagnostic value of reticulocyte hemoglobincontent in hemodialysis patients receiving recombinant human erythropoietin

Thesis

Diagnostic value of reticulocyte hemoglobincontent in hemodialysis patients receiving recombinant human erythropoietin

Thesis

Serum insulin like growth factor-I indiabetic patients with macrovascular complications

Thesis

Effect of haemodialysis on hepatocyte growth factor level in diabetic patients with chronic renal failure

Thesis

Insulin-like growth factor i and bone turnover markers in liver cirrhosis

Thesis

CMV seropositivity determines Epoetin dose and hemoglobin levels in patients with CKD